Company Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 114 |
| CEO | Leon Moulder |
Contact Details
Address: North Building, Suite 1200 Waltham, Massachusetts 02451 United States | |
| Phone | (857) 271-2954 |
| Website | zenasbio.com |
Stock Details
| Ticker Symbol | ZBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001953926 |
| CUSIP Number | 74347B193 |
| ISIN Number | US74347B1935 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leon O. Moulder, Jr. | Chief Executive Officer and Chairman of the Board of Directors |
| Joseph Farmer | President and Chief Operating Officer |
| Jennifer Fox | Chief Business Officer and Chief Financial Officer |
| Orlando Oliveira | Chief Commercial Officer |
| Patricia Allen | Director |
| James Boylan | Director |
| Patrick Enright | Director |
| Tomas Kiselak | Director |
| Hongbo Lu, Ph.D. | Director |
| Jake Nunn | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 16, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 424B4 | Prospectus |
| Sep 12, 2024 | EFFECT | Notice of Effectiveness |
| Sep 12, 2024 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Sep 12, 2024 | CERT | Certification by an exchange approving securities for listing |